Systematic Review of Primary and Booster COVID-19 Sera Neutralizing Ability Against SARS-CoV-2 Omicron Variant

Overview

Journal NPJ Vaccines

Date 2022 Nov 15

PMID 36379935

Authors

Ioannis Sitaras

Henning Jacobsen

Melissa M Higdon

William E Dowling

Naor Bar-Zeev

Maria Deloria Knoll

Affiliations

Soon will be listed here.

Abstract

Virus neutralization data using post-vaccination sera are an important tool in informing vaccine use policy decisions, however, they often pose interpretive challenges. We systematically reviewed the pre-print and published literature for neutralization studies against Omicron using sera collected after both primary and booster vaccination. We found a high proportion of post-primary vaccination sera were not responding against Omicron but boosting increased both neutralizing activity and percent of responding sera. We recommend reporting percent of responders alongside neutralization data to portray vaccine neutralization ability more accurately.

Citing Articles

A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories.

Brangel P, Tureli S, Muhlemann B, Liechti N, Zysset D, Engler O Viruses. 2025; 16(12).

PMID: 39772242 PMC: 11680265. DOI: 10.3390/v16121936.

Evaluating the Quality of Studies Assessing COVID-19 Vaccine Neutralizing Antibody Immunogenicity.

Katzmarzyk M, Naughton R, Sitaras I, Jacobsen H, Higdon M, Knoll M Vaccines (Basel). 2024; 12(11).

PMID: 39591141 PMC: 11598362. DOI: 10.3390/vaccines12111238.

COVID-19 Vaccine Effectiveness Studies against Symptomatic and Severe Outcomes during the Omicron Period in Four Countries in the Eastern Mediterranean Region.

Runge M, Karimian Z, Kheirandish M, Borghi G, Wodniak N, Fahmy K Vaccines (Basel). 2024; 12(8).

PMID: 39204033 PMC: 11360574. DOI: 10.3390/vaccines12080906.

Verburgh M, Boyd A, Schim van der Loeff M, Bakker M, Wit F, Van Der Valk M Open Forum Infect Dis. 2024; 11(7):ofae380.

PMID: 39070044 PMC: 11273239. DOI: 10.1093/ofid/ofae380.

SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition.

Fischer C, Willscher E, Paschold L, Gottschick C, Klee B, Diexer S NPJ Vaccines. 2024; 9(1):23.

PMID: 38316833 PMC: 10844289. DOI: 10.1038/s41541-024-00815-1.

References

Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C . mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med. 2022; 28(3):477-480. PMC: 8767537. DOI: 10.1038/s41591-021-01676-0. View

Wang K, Jia Z, Bao L, Wang L, Cao L, Chi H . Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature. 2022; 603(7903):919-925. PMC: 8967717. DOI: 10.1038/s41586-022-04466-x. View

Cameroni E, Bowen J, Rosen L, Saliba C, Zepeda S, Culap K . Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022; 602(7898):664-670. PMC: 9531318. DOI: 10.1038/s41586-021-04386-2. View

Arien K, Heyndrickx L, Michiels J, Vereecken K, Van Lent K, Coppens S . Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant. NPJ Vaccines. 2022; 7(1):35. PMC: 8904765. DOI: 10.1038/s41541-022-00459-z. View

Zhou R, To K, Peng Q, Chan J, Huang H, Yang D . Vaccine-breakthrough infection by the SARS-CoV-2 omicron variant elicits broadly cross-reactive immune responses. Clin Transl Med. 2022; 12(1):e720. PMC: 8792449. DOI: 10.1002/ctm2.720. View

Syed A, Ciling A, Taha T, Chen I, Khalid M, Sreekumar B . Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. Proc Natl Acad Sci U S A. 2022; 119(31):e2200592119. PMC: 9351483. DOI: 10.1073/pnas.2200592119. View

Seki Y, Yoshihara Y, Nojima K, Momose H, Fukushi S, Moriyama S . Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. Med. 2022; 3(6):406-421.e4. PMC: 9040508. DOI: 10.1016/j.medj.2022.04.013. View

Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E, Cho A . Plasma Neutralization of the SARS-CoV-2 Omicron Variant. N Engl J Med. 2022; 386(6):599-601. PMC: 8757565. DOI: 10.1056/NEJMc2119641. View

Yu X, Wei D, Xu W, Li Y, Li X, Zhang X . Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination. Cell Discov. 2022; 8(1):4. PMC: 8761745. DOI: 10.1038/s41421-022-00375-5. View

10.

Tada T, Zhou H, Dcosta B, Samanovic M, Chivukula V, Herati R . Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. EBioMedicine. 2022; 78:103944. PMC: 9021600. DOI: 10.1016/j.ebiom.2022.103944. View

11.

Muik A, Lui B, Wallisch A, Bacher M, Muhl J, Reinholz J . Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science. 2022; 375(6581):678-680. PMC: 9836206. DOI: 10.1126/science.abn7591. View

12.

Lu L, Yee Mok B, Chen L, Chan J, Tsang O, Lam B . Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. Clin Infect Dis. 2021; 75(1):e822-e826. PMC: 8754807. DOI: 10.1093/cid/ciab1041. View

13.

Cheng S, Mok C, Leung Y, Ng S, Chan K, Ko F . Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med. 2022; 28(3):486-489. PMC: 8940714. DOI: 10.1038/s41591-022-01704-7. View

14.

Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Kanno T . Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. Med. 2022; 3(4):249-261.e4. PMC: 8894731. DOI: 10.1016/j.medj.2022.02.006. View

15.

Cheng S, Lin Y, Chen C, Cheng C . Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222. Vaccines (Basel). 2022; 10(10). PMC: 9609613. DOI: 10.3390/vaccines10101701. View

16.

Kitchin D, Richardson S, van der Mescht M, Motlou T, Mzindle N, Moyo-Gwete T . Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern. Cell Rep Med. 2022; 3(3):100535. PMC: 8828412. DOI: 10.1016/j.xcrm.2022.100535. View

17.

Wang X, Zhao X, Song J, Wu J, Zhu Y, Li M . Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerg Microbes Infect. 2022; 11(1):477-481. PMC: 8820826. DOI: 10.1080/22221751.2022.2030200. View

18.

Banerjee A, Lew J, Kroeker A, Baid K, Aftanas P, Nirmalarajah K . Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. Med. 2022; 3(6):422-432.e3. PMC: 9008123. DOI: 10.1016/j.medj.2022.04.002. View

19.

Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J . Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022; 602(7898):671-675. DOI: 10.1038/s41586-021-04389-z. View

20.

Cele S, Jackson L, Khoury D, Khan K, Moyo-Gwete T, Tegally H . Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022; 602(7898):654-656. PMC: 8866126. DOI: 10.1038/s41586-021-04387-1. View